Balyasny Asset Management
DTIL icon

Balyasny Asset Management’s Precision BioSciences DTIL Stock Holding History

Balyasny Asset Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-189,665
Closed -$905K – 2947
2025
Q1 		$905K Buy
+189,665
New +$965K ﹤0.01% 2036
2022
Q4 		– Sell
-644
Closed -$25K – 2879
2022
Q3 		$25K Buy
644
+265
+70% +$12.6K ﹤0.01% 2554
2022
Q2 		$18K Buy
+379
New +$22.2K ﹤0.01% 2499
2021
Q2 		– Sell
-5,499
Closed -$1.71M – 2049
2021
Q1 		$1.71M Buy
+5,499
New +$1.93M 0.01% 1079

Other funds holding DTIL

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Balyasny Asset Management's DTIL Position: Q2 2025 in Review

Balyasny Asset Management sold out of Precision BioSciences (DTIL) in Q2 2025, closing a stake of 189,665 shares — an estimated $905K sold.

Balyasny Asset Management first reported a position in DTIL in Q1 2021 and held it in 4 quarters. The position peaked at $1.71M in Q1 2021. 52 funds tracked by Wall St. Rank hold DTIL as of Q2 2025.

  • Balyasny Asset Management reported no remaining Precision BioSciences position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 189,665 Precision BioSciences shares in Q2 2025, an estimated $905K.
  • Balyasny Asset Management first reported a position in Precision BioSciences in Q1 2021 and held it in 4 quarters.
  • Balyasny Asset Management's Precision BioSciences position peaked at $1.71M in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.